Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04641429
Other study ID # UW 19-005
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2019
Est. completion date October 2021

Study information

Verified date November 2020
Source The University of Hong Kong
Contact Tatia Lee, PhD
Phone 852-39178394
Email tmclee@hku.hk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates the effects of exercise on older people's cognitive and affective functions, and the possible underlying neurobiological pathways.


Description:

Population aging is accelerating. The socioeconomic burden associated with an aging population calls for timely action for promoting brain health. The human brain has the capacity for plastic reorganization through learning and experience. Physical activity could induce plasticity and is important in the prevention of functional decline and increased survival. In this study, the effects of Qigong and stretching exercise on affective and cognitive function among the healthy elderly are investigated. This study is proposed to invite 200 participants (100 in each intervention condition). The investigators acquire data from questionnaires, assessments, neurocognitive tests, magnetic resonance imaging and blood samples at baseline (before the intervention) and post-intervention.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date October 2021
Est. primary completion date October 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 70 Years
Eligibility Inclusion Criteria: 1. At least finished primary school; 2. Have normal or corrected-to-normal vision and hearing; 3. Ability to do exercise; 4. Right-hand dominance; 5. Normal cognitive ability as assessed by the Montreal Cognitive Assessment Hong Kong version (HK-MoCA). Exclusion Criteria: 1. Abmormal anxiety or depression mood as measured by the Hospital Anxiety and Depression Scale; 2. Current diagnosis or history of neurological or psychological conditions, such as substance abuse, psychotic disorders, or affective disorders; 3. Current diagnosis or history of substance/alcohol abuse; 4. Contraindications for MRI scanning (e.g. implanted metal); 5. People who regularly practice any qigong, Tai Chi or similar exercise or meditation within 6 months before study; 6. People who regularly practice moderate to high intensity physical exercise within 6 months before study. The operational definition of 'regular practice' is three times a week or more, at least 30 mins per time for at least 3 months.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Qigong exercise
Participants in the experimental group receive 12-week group-based Qigong exercise training.
Stretching exercise
Participants in the control group receive 12-week group-based stretching exercise training.

Locations

Country Name City State
Hong Kong The University of Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change from Baseline in cognitive processing speed scores on the Symbol Digit Modalities Test at 12 Weeks Changes of cognitive processing speed scores are measured by the Symbol Digit Modalities Test from baseline to end of intervention at 12 Weeks. Scores on the Symbol Digit Modalities Test range from 0-90, with a higher score indicating better performance. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in sustained attention scores on the Continuous Performance Test at 12 Weeks Changes of sustained attention scores are measured by the Continuous Performance Test from baseline to end of intervention at 12 weeks. The accuracy scores on the Continuous Performance Test range from 0-100%, with a higher score indicating better performance. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in working memory scores on the Digit Span-Backward Test at 12 Weeks Changes of working memory scores are measured by the Digit Span Backward Test from baseline to end of intervention at 12 weeks. Scores on the Digit Span-Backward test range from 2-13, with a higher score indicating better performance. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in language scores on the Rapid Naming Test at 12 Weeks Changes of language scores are measured by the Rapid Naming Test from baseline to end of intervention at 12 weeks. Scores on the Rapid Naming Test range from 0-36, with a higher score indicating better performance. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in trait affect scores on the Chinese Affect Scale at 12 Weeks Changes of trait positive affect and negative affect are measured by the Chinese Affect Scale from baseline to end of intervention at 12 weeks. Positive and negative affect scores on Chinese Affect Scale both range from 10-50, with a higher score indicating higher positive/negative affect. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in affective processing by the Emotion Processing Task at 12 weeks Changes of affective stimuli processing are measured by the Emotion Processing Task from baseline to end of intervention at 12 weeks. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in blood levels of cortisol at 12 Weeks Changes of blood biomarker levels of cortisol are measured from baseline to end of intervention at 12 weeks. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in blood levels of interleukin-6 at 12 Weeks Changes of blood biomarker levels of interleukin-6 are measured from baseline to end of intervention at 12 weeks. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in blood levels of brain-derived neurotrophic factor at 12 Weeks Changes of blood biomarker levels of brain-derived neurotrophic factor are measured from baseline to end of intervention at 12 weeks. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in telomerase activity at 12 Weeks Changes of blood measurement of telomerase activity are measured from baseline to end of intervention at 12 weeks. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in brain structure by magnetic resonance imaging at 12 Weeks Changes of brain structure are measured by T1-weighted magnetic resonance imaging from baseline to end of intervention at 12 Weeks. from baseline to end of intervention at 12 weeks
Primary Mean change from Baseline in brain function by functional magnetic resonance imaging at 12 Weeks Changes of brain function are measured by functional magnetic resonance imaging from baseline to end of intervention at 12 Weeks. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in perceived stress scores on the Perceived Stress Scale at 12 weeks Changes of perceived stress scores are measured by the Perceived Stress Scale from baseline to end of intervention at 12 weeks. Scores on the Perceived Stress Scale range from 0-56, with a higher score indicating higher perceived stress. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in insomnia severity scores on the Insomnia Severity Index at 12 weeks Changes of insomnia severity scores are measured by the Insomnia Severity Index from baseline to end of intervention at 12 weeks. Scores on the Insomnia Severity Index range from 0-28, with a higher score indicating more severe insomnia. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in quality of sleep on the Pittsburg Seep Quality Index at 12 weeks Changes of quality of sleep scores are measured by the Pittsburg Seep Quality Index from baseline to end of intervention at 12 weeks. Scores on the Pittsburg Seep Quality Index range from 0-21, with a higher score indicating more severe sleeping difficulty. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in depression and anxiety scores on the Hospital Anxiety and Depression Scale at 12 weeks Changes of depression and anxiety scores are measured by the Hospital Anxiety and Depression Scale from baseline to end of intervention at 12 weeks. Anxiety and Depression scores on the Hospital Anxiety and Depression Scale both range from 0-21, with a higher score indicating more severe anxiety/depression mood. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in perceived loneliness scores on the UCLA Loneliness Scale at 12 weeks Changes of perceived loneliness scores are measured by the UCLA Loneliness Scale from baseline to end of intervention at 12 weeks. The scores on the UCLA Loneliness Scale range from 20-80, with a higher score indicating greater perceived loneliness. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in quality of life scores on the WHO Quality of Life-BREF scale at 12 weeks Changes of quality of life scores are measured by the WHO Quality of Life-BREF scale from baseline to end of intervention at 12 weeks. The scores on the WHO Quality of Life-BREF scale range from 26-130, with a higher score indicating higher quality of life. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in emotion reactivity scores on the Emotion Reactivity Scale at 12 weeks Changes of emotion reactivity scores are measured by the Emotion Reactivity Scale from baseline to end of intervention at 12 weeks. The scores on the Emotion Reactivity Scale range from 0-84, with a higher score indicating greater emotional reactivity. from baseline to end of intervention at 12 weeks
Secondary Mean change from Baseline in somatization scores on the somatization subscale of Symptom Check-List-90 at 12 weeks Changes of somatization scores are measured by the somatization subscale of Symptom Check-List-90 from baseline to end of intervention at 12 weeks. Scores on the somatization subscale of Symptom Check-List-90 range from 0-48, with a higher score indicating greater somatization. from baseline to end of intervention at 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05703945 - Efficacy of a Toe Flexion Training Protocol on Older Adults' Mobility N/A
Terminated NCT03594097 - Use of Coconut Nourish and Queen Garnet Plum to Improve Health in an Elderly Population N/A
Recruiting NCT06056180 - The Effect of Motor Image Training on Balance Performance in Geriatric Individuals N/A
Recruiting NCT04897191 - Healthy Age-dependent Reference Values for Microvascular Structure and Function
Not yet recruiting NCT05744492 - Multicomponent Exercise Program on the Intrinsic Capacity (ICOPE) of Community-dwelling Older Adults in Primary Care N/A
Recruiting NCT05592093 - Effect of Korean Red Ginseng on Oxidation in Middle-aged and Elderly Sub-health Population Phase 2/Phase 3
Active, not recruiting NCT03405675 - Gerontology Research Programme: The Singapore Longitudinal Ageing Studies (SLAS I & II)
Completed NCT03830762 - Xanamemâ„¢ in Healthy Elderly Subjects Phase 1
Active, not recruiting NCT04536870 - Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study N/A
Completed NCT02996578 - Effect of Polyphenol-rich Cocoa Products on Cognitive Function N/A